Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Runcaciguat in Renal Impairment
NCT03235076Phase 1Completed
- Sponsor
- Bayer
- Start
- Aug 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of runcaciguat in chronic kidney disease (CKD) (4 arms), sponsored by Bayer. Primary endpoints: Area under the concentration vs. time curve from zero to infinity, Maximum observed drug concentration and 2 more. Started Aug 2017; status: completed.
02
Drugs
runcaciguat
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT03235076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03235076.